Rigel Pharmaceuticals (RIGL) has disclosed a new risk, in the Corporate Activity and Growth category.
Rigel Pharmaceuticals’ strategy to augment its hematology and oncology portfolio through self-driven expansion, acquisitions, in-licensing, or partnerships harbors considerable risk. Despite recent successes, such as the FDA approval of REZLIDHIA and the acquisition of GAVRETO, the company faces intense competition and the challenge of integrating new assets into its existing framework. The due diligence process may fail to disclose all liabilities, and there is no guarantee that Rigel Pharmaceuticals can maintain key relationships or smoothly transition patients and manufacturing post-acquisition. Ultimately, the firm’s ambitious growth endeavors are fraught with the perils of unanticipated expenses, legal entanglements, and the inherent uncertainty of drug development and commercialization.
Overall, Wall Street has a Moderate Buy consensus rating on RIGL stock based on 1 Buy and 2 Holds.
To learn more about Rigel Pharmaceuticals’ risk factors, click here.
